Cryoport, Inc. (CYRX)
| Market Cap | 874.48M+77.0% |
| Revenue (ttm) | n/a-8.0% |
| Net Income | n/a-148.2% |
| EPS | n/a-161.7% |
| Shares Out | 50.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,170,854 |
| Open | 17.36 |
| Previous Close | 17.80 |
| Day's Range | 17.13 - 17.55 |
| 52-Week Range | 7.61 - 18.36 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.21(+10.72%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CYRX stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CYRX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 24, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 24, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 23, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 6, 2020 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 6, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 5, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 17, 2020 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 17, 2020 |
Recently reported changes in CYRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CYRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CYRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CYRX Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Segment Reporting | $48.97M | 82.59% |
| Adjusted EBITDA for reportable segments | $5.94M | 10.02% |
| Investment income | $3.13M | 5.28% |
| Cost, rent | $600.00K | 1.01% |
| Cost, stock-based compensation | $400.00K | 0.67% |
| Engineering and development, stock based compensation | $200.00K | 0.34% |
| Change in fair value of contingent consideration | $48.00K | 0.08% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CYRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CYRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CYRX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $24.38M |
| IWMiShares Russell 2000 ETF | $23.00M |
| VXFVanguard Extended Market ETF | $9.36M |
| DFASDimensional - US Small Cap ETF | $5.46M |
| SCHASchwab U.S. Small-Cap ETF | $4.75M |
| VTWOVanguard Russell 2000 ETF | $4.55M |
Estimated from each fund’s disclosed top holdings × AUM
CYRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CYRX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score